Similar articles

• Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2).

  Allen JD, Schinkel AH. Allen JD, et al. Mol Cancer Ther. 2002 Apr;1(6):427-34. Mol Cancer Ther. 2002. PMID: 12477055 Review. No abstract available.
• Drug resistance in hematologic malignancies.

  Marie JP. Marie JP. Curr Opin Oncol. 2001 Nov;13(6):463-9. doi: 10.1097/00001622-200111000-00008. Curr Opin Oncol. 2001. PMID: 11673686 Review.
• Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

  Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH. Jonker JW, et al. J Natl Cancer Inst. 2000 Oct 18;92(20):1651-6. doi: 10.1093/jnci/92.20.1651. J Natl Cancer Inst. 2000. PMID: 11036110
• Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.

  Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, Ambudkar SV, Chen ZS. Shi Z, et al. Cancer Res. 2007 Nov 15;67(22):11012-20. doi: 10.1158/0008-5472.CAN-07-2686. Cancer Res. 2007. PMID: 18006847
• Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate.

  Wang L, Liu L, Chen Y, Du Y, Wang J, Liu J. Wang L, et al. Pathol Res Pract. 2018 Sep;214(9):1467-1473. doi: 10.1016/j.prp.2018.08.001. Epub 2018 Aug 7. Pathol Res Pract. 2018. PMID: 30104076